Ranbaxy Axes Staff At Toansa API Site As Internal Probe Gains Speed
This article was originally published in PharmAsia News
Executive Summary
A thorough investigation launched by Ranbaxy following a U.S. FDA ban on its Toansa manufacturing site is slowly yielding results. Heads are starting to roll and more revelations are expected as the probe progresses.